Global Infectious Diseases Partnering 2016-2023: Deal trends, players and financials


Global Infectious Diseases Partnering 2016-2023: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectious partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
March 2023
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Global Infectious Diseases Partnering 2016 to 2023 provides the full collection of infectious diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016.


  • Trends in infectious diseases partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Infectious diseases partnering agreement structure
  • Infectious diseases partnering contract documents
  • Top infectious diseases deals by value
  • Most active infectious diseases dealmakers


Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.


The report takes readers through the comprehensive infectious diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering infectious diseases deals.


The report presents financial deal terms values for infectious diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.


The initial chapters of this report provide an orientation of infectious diseases dealmaking trends.


Chapter 1 provides an introduction to the report.


Chapter 2 provides an overview of the trends in infectious diseases dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.


Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.


Chapter 4 provides a review of the leading infectious diseases deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active infectious diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 5 provides comprehensive access to infectious diseases deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive directory of all infectious diseases partnering deals by specific infectious diseases target announced since 2016. The chapter is organized by specific infectious diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided with each report of all infectious diseases partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in infectious diseases partnering and dealmaking since 2016.  


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of infectious diseases technologies and products.


Report scope


Global Infectious Diseases Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to infectious diseases trends and structure of deals entered into by leading companies worldwide.


Global Infectious Diseases Partnering 2016 to 2023 includes:


  • Trends in infectious diseases dealmaking in the biopharma industry since 2016
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of infectious diseases deal contract documents
  • Comprehensive access to over 3,100 infectious diseases deal records
  • The leading infectious diseases deals by value since 2016
  • Most active infectious diseases dealmakers since 2016


The report includes deals for the following indications:

Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications

Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.


Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other fungal indications

Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever, Malaria, West Nile Virus, Yellow fever, plus other tropical indications


In Global Infectious Diseases Partnering 2016 to 2023, available deals and contracts are listed by:


  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 


The Global Infectious Diseases Partnering 2016 to 2023 report provides comprehensive access to available deals and contract documents for over 3,100 infectious diseases deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Infectious Diseases Partnering 2016 to 2023 provides the reader with the following key benefits:


  • In-depth understanding of infectious diseases deal trends since 2016
  • Access infectious diseases deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between infectious diseases partner companies
  • Comprehensive access to over 3,100 links to actual infectious diseases deals entered into by the world’s biopharma companies
  • Indepth review of infectious diseases deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner infectious diseases opportunities
  • Uncover companies actively partnering infectious diseases opportunities

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in infectious diseases dealmaking


2.1. Introduction

2.2. Infectious diseases partnering over the years          

2.3. Infectious diseases partnering by deal type

2.4. Infectious diseases partnering by industry sector

2.5. Infectious diseases partnering by stage of development

2.6. Infectious diseases partnering by technology type

2.7. Infectious diseases partnering by therapeutic indication


Chapter 3 –Financial deal terms for infectious diseases partnering


3.1. Introduction

3.2. Disclosed financials terms for infectious diseases partnering

3.3. Infectious diseases partnering headline values

3.4. Infectious diseases deal upfront payments

3.5. Infectious diseases deal milestone payments

3.6. Infectious diseases royalty rates


Chapter 4 – Leading infectious diseases deals and dealmakers


4.1. Introduction

4.2. Most active in infectious diseases partnering

4.3. List of most active dealmakers in infectious diseases         

4.4. Top infectious diseases deals by value


Chapter 5 – Infectious diseases contract document directory


5.1. Introduction

5.2. Infectious diseases partnering deals where contract document available


Chapter 6 – Infectious diseases dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by infectious diseases therapeutic target




Appendix 1 – Directory of infectious diseases deals by company A-Z since 2016

Appendix 2 – Directory of infectious diseases deals by deal type since 2016

Appendix 3 – Directory of infectious diseases deals by stage of development since 2016

Appendix 4 – Directory of infectious diseases deals by technology type sinc 2016

Further reading on dealmaking

Deal type definitions


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from CurrentPartnering


Table of figures


Figure 1: Infectious diseases partnering since 2016

Figure 2: Infectious diseases partnering by deal type since 2016

Figure 3: Infectious diseases partnering by industry sector since 2016

Figure 4: Infectious diseases partnering by stage of development since 2016

Figure 5: Infectious diseases partnering by technology type since 2016

Figure 6: Infectious diseases partnering by indication since 2016

Figure 7: Infectious diseases deals with a headline value

Figure 8: Infectious diseases deals with upfront payment values

Figure 9: Infectious diseases deals with milestone payment

Figure 10: Infectious diseases deals with royalty rates

Figure 11: Active infectious diseases dealmaking activity since 2016

Figure 12: Top infectious diseases deals by value since 2016

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,985: single site license
  • $17,975: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers., 2A, 3a-diagnostics, 3D BioMed, 3M, 3P Biopharmaceuticals, 3rd People’s Hospital of Shenzhen, 3SBio, 4Living Biotech, 7 Hills Pharma, 9 Meters Biopharma, 10X Genomics, 221b Foundation, A*STAR Institute of Microelectronics (IME), A*STAR Singapore Immunology Network, A*STAR’ Institute of Molecular and Cell Biology, A-Alpha Bio, A2A Pharmaceuticals, Aanika Biosciences, Aardvark Therapeutics, Aarhus University, Aarhus University Hospital, Aavis Pharmaceuticals, Abacus Diagnostica, AB Analitica, Abbott Laboratories, Abbott Rapid Diagnostics, Abbvie, AbCellera Biologics, ABEC, Abeome, Abera Bioscience, ABIVAX, ABK Remote Drug Testing, ABL Bio, Ablexis, Abnova, Abogen Biosciences, Aboundbio, Absolute Antibody, ABT Innovations, AbVacc, Abveris, Abzena, Academic Medical Center, Academy of Military Medical Sciences (China), AC Bioscience, Accelerated Enrollment Solutions, Accelerate Diagnostics, Access BIO, Acelrx Pharmaceuticals, Aceragen, Acer Therapeutics, Achaogen, ACON Biotech, Actelion, Actinium Pharmaceuticals, Active Motif, Acuant, Acurx Pharmaceuticals, Adagio Therapeutics, Ada Health, Adamis Pharmaceuticals, Adaptive Biotechnologies, Adaptive Phage Therapeutics, AdaptVac, Adeptrix, Adial Pharmaceuticals, Adimab, Aditx Therapeutics, Adjuvance Technologies, ADMA Biologics, ADS, Aduro BioTech, Advaccine Biotechnology, Advanced Animal Diagnostics, Advanced Biological Laboratories, Advanced BioNutrition, Advanced BioScience Laboratories, Advanced Regenerative Manufacturing Institute, Advanced Remote Monitoring, Advanz Pharma, Advarra, AdventHealth, Advent International, Adyton, Aegea Biotechnologies, Aegis Life, Aelix Therapeutics, Aerogen, Aerpio Pharmaceuticals, Aethlon Medical, Aetion, Affinity Biosciences, Affinivax, AffyXell Therapeutics, Africa Centres for Disease Control and Prevention, Africa Medical Supplies Platform, Africa Union, Afrigen Biologics, AGC Biologics, Age Labs, Agena Bioscience, Agenus Bio, AgeX Therapeutics, Agile Biodetection, Aglon, Agricultural Materials Company, AiCuris, AID Genomics, AIDS Foundation of Chicago, AIkido Pharma, AIM ImmunoTech, Ainos, AINQA Health, AiPharma Global Holdings, Airway Therapeutics, AIT Therapeutics, Ajinomoto Bio-Pharma Services, Akers Biosciences, Akida, Akili Interactive Labs, Ako Med, Akonni Biosystems, Akribis Systems, Akron Biotechnology, Akshaya Bio, Akston Biosciences, Alab, Alamar Biosciences, Alamo Pharma Services, Albany Molecular Research, Alberta Cell Therapy Manufacturing, Albert Einstein College of Medicine, ALBOT Technologies, Alcami, Alderley Analytical, Aldevron, AlgaEnergy, Algenex, Algernon Pharmaceuticals, Alibaba Health, Aligos Therapeutics, AlivaMab Discovery Services, ALK-Abello, Allderma, Allecra Therapeutics, Allergan, AlloVir, AllStar Health Brands, Alltests Clinical Solutions, Almirall, Alnylam Pharmaceuticals, Alpha-Tec Systems, Alphamab Biopharmaceuticals, Altamira Pharma, Altamira Therapeutics, Altan Pharma, Altasciences, Alterity Therapeutics, Altesa Biosciences, Altimmune, Altum Pharmaceuticals, Alveo Technologies, Alverno Clinical Laboratories, Alvogen, Al Zahrawi Medical Supplies, AM-Pharma, A Menarini Diagnostics, American Association for Laboratory Accreditation, American College of Chest Physicians, American Diabetes Association, American Foundation for AIDS Research (amfAR), American Gene Technologies, American Medical Depot, American Type Culture Collection (ATCC), Amerigen Pharmaceuticals, Amerimmune, AmerisourceBergen, Amerlux, Ametek, Amgen, Amicogen, Amicrobe, Amneal Pharmaceuticals, Amomed Pharma, AmpliPhi Biosciences, Amplity Health, Amplyx Pharmaceuticals, AMP Therapeutics, AMR, AMS, Amyndas Pharmaceuticals, Amyris, AN2 Therapeutics, Analog Devices, Anatara Lifesciences, ANA Therapeutics, Anavasi Diagnostics, Angelini Pharma, AnGes MG, ANI Pharmaceuticals, Anixa Biosciences, Annar Health Technologies, Anova Enterprises, ANP Technologies, Antabio, Antengene, Anteo Diagnostics, AnteoTech, AntibioTx, Antios Therapeutics, Antisoma Therapeutics, Aperiomics, Apex Global Brands, Aphex BioCleanse Systems, Aphios, ApolloBio, Apollo Med Innovations, Apotex, Appili Therapeutics, Apple, Applied Biology, Applied Botanics, Applied DNA Sciences, Applied Pharmaceutical Innovation, Applied UV, Aptagen, Aptahem, Aptar CSP Technologies, Aptevo Therapeutics, Aptimmune Biologics, Aptorum Group, Aptuit, Aqemia, Aradigm, Aragen Bioscience, Aralez Pharmaceuticals, Arbor Biosciences, Arbutus, ARCA Biopharma, ArcDia, Arches Research, Arctoris, Arcturus Therapeutics, Ardigen, Ares Genetics, Ares Life Sciences, Areum Bio, AREV Nanotech Brands, Argonne National Laboratory, Ariadne Genomics, Aridea Solutions, Aridis Pharmaceuticals, Arisan Therapeutics, ARISE MD Integrative Medicine & Surgery, Arixa Pharmaceuticals, Arizona State University, Arkansas Children's Research Institute, Ark Biosciences, Arlington Scientific, Armata Pharmaceuticals, Armed Forces Medical Research Institute, Armis Biopharma, Arrevus, Arrowhead Pharmaceuticals, Arrow Pharmaceuticals, Arsanis Biosciences, ArtemiLife, Artes Biotechnology, Artificial, Artizan Biosciences, ARUP Laboratories, Ascendent Capital Partners, Ascletis, Asep Medical, Asopharma, Assembly Biosciences, Assertio Therapeutics, Astellas Pharma, Astra Formedic, AstraZeneca, Atara Biotherapeutics, Atea Pharmaceuticals, Atnahs Pharma, Atomo Diagnostics, Atomwise, Atossa Therapeutics, ATP, Atreca, Atrys Health, Attana, Attillaps Holdings, ATUM, Auburn University, Audax Medical, Audere, Augmenta, AUM LifeTech, AuraVax Therapeutics, Aurobindo Pharma, Australian Medical Research Institute, Australian Research Council, Austrian Research Promotion Agency, Autobio Diagnostics, Avacta, Avails Medical, Avalon GloboCare, Avalon SteriTech, Avalo Therapeutics, AvantGen, Avanzcare, Avellino Labs, Avera McKennan, Avernus Pharma, Aveshka, Avid Bioservices, Avidea Technologies, Aviragen Therapeutics, AVIR Pharma, Avisa Pharma, Avivagen, Avricore Health, Avrok Laboratories, Axela, AXIM Biotechnologies, Axiom Real-Time Metrics, Axis Lighting, Aytu BioPharma, Azitra, AzurRx BioPharma, Babson Diagnostics, Bachem, Baebies, Banco de Sangre de Servicios Mutuos, Bank of China Group Investment, Barbara Ann Karmanos Cancer Institute, Baruch S Blumberg Institute, BASE10 Genetics, BASF, Basilea Pharmaceutica, Batavia Biosciences, Bateman Horne Center, BATM, Battelle, Bavarian Nordic, Baxter International, Bay Area Lyme Foundation, Bayer, Bayer CropScience, Bayer Healthcare, Baylor College, Baylor College of Medicine, BB100, BBI Solutions, BC Neuroimmunology, BC Platforms, Beckman Coulter, Becton Dickinson, BeiGene, Beijing Defengrei Biotechnology, Beijing Genomics Institute (BGI), Beijing Keyuan Xinhai Pharma, Beijing Minhai Biotechnology, Belfor, Belkin, Benchmark Electronics, BE Pharmaceuticals, Berg, Berkeley Lights, Beroni Group, Bestbion, Best Choice, Best Supplies, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, BetterLife Pharma, BGN Technologies, Bharat Biotech, BIA Separations, Bill and Melinda Gates Foundation, BillionToOne, Binex, Bintai Kinden, Binx Health, Bio-Cide International, Bio-Manguinhos, Bio-Manguinhos/Fiocruz, Bio-Rad Laboratories, Bio-Techne, BioAnalytical Systems, BioAsia, BIOASTER, BioCanna Healthcare, BioCentriq, Biocept, BioCheck, BioClonetics Immunotherapeutics, BioComo, Biocomposites, Biocom Purchasing Group, Biocon, BioCopy, BioCryst Pharmaceuticals, Biodesix, Biodextris, Biodirection, BioExcel Diagnostics, Biofabri, Biofactura, Bio Farma, Biofortis, Bioforum, Biogen, BIOgenetiX, BioGX, Bioharmony Therapeutics, Biohaven Pharmaceuticals, BioHEP Technologies, BioHiTech Global, Biohit Healthcare, BioIQ, BioIVT, BioLab Sciences, Biolase, Biolexis, Biolife Science, BioLife Solutions, BioLink Life Sciences, Biological E, bioLytical Laboratories, BioMatrix Specialty Pharmacy, Biomedical Advanced Research and Development Authority, Biomeme, Biomerica, bioMerieux, Biomica, bioMONTR Labs, BiondVax, BioNet Holding, BioNTech, BionX Medical Technologies, Biophage Pharma, BioPharma Plasma, BioPhausia, Biophore Pharmaceuticals, Bio Products Laboratory, bioRASI, BioReference Laboratories, Biosenta, BioSig Technologies, BioSun Pharmed, BioSure, BioSymetrics, Biosynex, BioSyntagma, Biotechnology Industry Research Assistance Council, Biotecom, BioTecon Diagnostics, BioTek reMEDys, Biotest, Biotron Laboratories, Biovac, BioVaxys, BioVersys, Blacksmith Medicines, Blackstone, Blanver, Blood Systems Research Institute, Blu Biotech, Bluejay Diagnostics, BlueJay Therapeutics, Blue Water Resolute Innovations, Blue Water Vaccines, BlueWillow Biologics, BMV Medica, BND, Boca Biolistics, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Boeing Company, Bohai Biomedical, Bold Therapeutics, Bonne Santé Group, Booz Allen, Boragen, Bosch, Boston Immune Technologies and Therapeutics, Boston Pharmaceuticals, Boston University, Botanical Solution, Boulos and Cooper Pharmaceuticals, Bpifrance, BPL Medical Technologies, Brahms, Brandeis University, BravoVax, Breathtec BioMedical, BreathTech, Brickell Biotech, Brigham and Women's Hospital, Brii Biosciences, Brik, Brill Pharma, Brio Systems, Briotech, Bristol-Myers Squibb, Broad Institute, Brown University, Bruker, BTG, Bugworks, Buoy Health, Burkhan Group, Burnet Institute, BurstIQ, Butantan Institute, C3J Therapeutics, Cadila Pharmaceuticals, Caerus Discovery, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Calithera Biosciences, Calliditas Therapeutics, Calvert Laboratories, Camber Pharmaceuticals, Cambridge Blockchain, Cambridge Consultants, Canabo Medical Clinics, Canadian Institutes of Health Research, Canary Health Technologies, Cancer Prevention and Research Institute of Texas, Cancer Research UK, Candel Therapeutics, Cannabis Science, CanSinoBIO, Cantex Pharmaceuticals, Cap Alter Pharma, Capitainer, Capricor Therapeutics, Caprion Biosciences, Caprisa, Capstone Health Alliance, CARB-X, Cardea Bio, Cardinal Health, Cardiomatics, Cardiome Pharma, Care Access Research, CareDx, Carestream Health, CaroGen, Carolina Liquid Chemistries, Carpegen, Carterra, Cascade Chemistry, Case Western Reserve University, CASI Pharmaceuticals, Caster Medical System, Catabasis Pharmaceuticals, Catalent, Catholic University Leuven, CCT Research, CDH Capital, CDR Laboratories, Ceapro, Celdara Medical, Cellect Biotechnology, Cellex, Cellix Bio, CellSafe, Celltrion, Cellvera, Celonic, Celsion, Celularity, Cenetron, Cenexi, Centene, Center for Cancer and Blood Disorders, Center for Human Genetics and Laboratory Medicine, Center for Infectious Disease Research, Center Point Clinical Services, Centers for Disease Control and Prevention, Centivax, Centogene, Central Association for the Blind and Visually Impaired, Centre for Drug Research and Development (CDRD), Centre for Human Drug Research, Cepheid, Cerba HealthCare, Ceres Nanosciences, Certara, CerTest Biotec, Certify, Cerus, Ceva Sante Animale, Cevec Pharmaceuticals, Changchun BCHT Biotechnology, Chan Zuckerberg Initiative, Charak Foundation, Chargeurs, Charite Universitatsmedizin Berlin, Charles River Laboratories, Chembio Diagnostics, ChemDiv, Chemipal, Children's Hospital Boston, Children's Hospital of Philadelphia, Chime Biologics, Chimerix, Chimeron Bio, China Medical System, China Meheco, China National Biotech Group (CNBG), China Resources Pharmaceutical Commercial Group International Trading, Chinese Academy of Sciences, ChromaDex, Chroma Therapeutics, Chromocell, Chronolife, Chubu University, Chugai Pharmaceutical, CIC Health, Ciclofilin Pharmaceuticals, Cidara Therapeutics, Cigna Healthcare, Cilag AG, CimCure, Cincinnati Children’s Hospital Medical Center, Ciox Health, Cipher Pharmaceuticals, Cipla, Circassia, Circuit Clinical, CIRION BioPharma Research, Citius Pharmaceuticals, Citranvi Biosciences, City College of New York, City of Corpus Christi, City of Hope, City University of New York Center for Advanced Technology, Civica Rx, Clarametyx Biosciences, CLEAR, Clear Creek Bio, Cleared4, ClearMask, ClearPath, Cleveland Clinic, ClinCapture, Clinical Enterprise, Clinical Reference Laboratory, ClinicalRM, Clinical Trial and Consulting Services, Clinigen, Clinton Health Access Initiative, Clorox Company, Clover Biopharmaceuticals, CLX Health, CMC Biologics, CN Bio, CNS Pharmaceuticals, Co-Defend, Co-Diagnostics, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Cocrystal Pharma, Codagenix, Codetta Biosciences, Codexis, Codiak BioSciences, Cogen Immune Medicines, CohBar, Cole-Parmer Instrument Company, Colombia Ministry of Health and Social Protection, Colorado State University, Columbia University, Colzyx, Commonwealth of Pennsylvania, Conatus Pharmaceuticals, Confirm BioSciences, ConserV Bioscience, Contakt World Technologies, ContraFect, ContraVir Pharmaceuticals, Cooper Companies, Cooper Pharma, COPAN, Copan Diagnostics, COPD Foundation, CORAT Therapeutics, Cord Blood Registry, Corden Pharma, CoreBiome, Corlexia Clinical Services, Cornell University, Corona Diagnostics, Corpometria Institute, Correvio Pharma, Cosmo Pharmaceuticals, Cosmos Holdings, CosmosID, Courtagen Life Sciences, Covar Pharmaceuticals, COVAX, COVAXX, Covistat, CPT Medical, CQuentia, CreaGen Biosciences, Creoptix, Crestone Pharma, Cristal Therapeutics, Croda, Cromos Pharma, Crown Laboratories, Crozet BioPharma, CR Pharma, Cruinn Diagnostics, CSIR - Institute of Microbial Technology, CSIRO, CSL, CSL Behring, CSPC Pharmaceutical Group, Cubic, Cue Biopharma, Cue Health, Cullinan Oncology, Cumberland Pharmaceuticals, Cupron, Curapath, Curative, Curative Biotechnology, Curebase, CURE Pharmaceutical, Curetis, CureVac, Curia, Current Health, CVC, CVD Equipment, CyanVac, Cyclacel Pharmaceuticals, Cyclenium Pharma, Cyclica, Cyclolab, Cynergy Wellness, Cyon Therapeutics, Cystic Fibrosis Foundation, Cystron Biotech, Cytiva, CytoAgents, Cytocom, Cytodyn, CytoSorbents, CytoVale, Cytovance Biologics, CYTOVIA Therapeutics, Cyxone, Daewoong Pharmaceutical, DAKOTA Life Sciences, Dalberg, Dalrada Health, Dalriada Drug Discovery, Dalton Pharma Services, Dana-Farber Cancer Institute, Dante Labs, Dare Bioscience, Dartmouth-Hitchcock Medical Center, Dartmouth College, DaRui Biotech, DASA, Dascena, DASH Analytics, DATANet Software Development, Datavant, Da Volterra, Daxor, Day Zero Diagnostics, DCN Diagnostics, DDL Diagnostic Laboratory, Debiopharm, Decibel Therapeutics, DeciBio Consulting, Decision Diagnostics, deCODE Genetics, Defence Science and Technology Laboratory, Defense Advanced Research Projects Agency, Defense Health Agency (US), Defense Threat Reduction Agency, Deinove, deKhon Global, Dell Medical School, Delpharm, DelSiTech, Denovium, Denso, Department of Defence, Department of Defense, Department of Health and Human Services, Department of Homeland Security, Department of Public Health, Department of Veterans Affairs, Dermapharm, Destiny Pharma, Devonian Health Group, Dewpoint Therapeutics, DiaCarta, DiaSorin, Diassess, Dicerna Pharmaceuticals, Diffusion Pharmaceuticals, DiNonA, Diomics, DiosCURE Therapeutics, DIOSynVax, Discuva, Diversey Care, DKSH, DMTC, DNA Electronics, DNA Link, DnaNudge, DoctorsOne Healthcare Systems, DongKoo Bio & Pharma, Donnelley Financial Solutions, Door Pharmaceuticals, Dorizoe Lifesciences, Dow Chemical, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Drawbridge Health, Drexel University, Dr Ho Now Health Products, Drug Innovation Ventures at Emory, Drugs for Neglected Diseases Initiative, DSG, Duality Technologies, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University, Duke University Medical Center, DuPont, Durect, Dyadic International, Dymax, Dynamic Blending, Dynasty Castle Investments, Dynavax Technologies, DynPort Vaccine Company, E25Bio, Easton Pharmaceuticals, Eckerd College, EcoGroup USA, Ecolog International, Eddingpharm, Edesa Biotech, Edge Pharma, Eiger BioPharmaceuticals, Eisai, Eisai Inc, Eisai S.A.S, EKF Diagnostics, Elanco, Elasmogen, ELC Group, ElectroCore, Elektrofi, Eleven Biotherapeutics, Eligo Bioscience, EligoChem, Eli Lilly, Elixirgen, Ellume, EluSys Therapeutics, Embleema, Emcure Pharmaceuticals, eMed, Emerald Organic Growth, Emergent BioSolutions, Emergex Vaccines, Emery Pharma, Emmes, EMM Life Science, Emory Healthcare, Emory University, Empatica, Empowered Diagnostics, Emulate, Enable Biosciences, Enamine, ENA Respiratory, EnBiotix, Ender Diagnostics, Endo International, Endpoint Health, Enesi Pharma, EnGeneIC, Engility, Enlivex, Ennaid Therapeutics, Enochian Biosciences, Ensensor, Entasis Therapeutics, Entos Pharmaceuticals, Enumeral Biomedical, Environmental Protection Agency (USA), ENYO Pharma, Enzo Biochem, Enzolytics, Enzychem Lifesciences, Enzymatica, Epidemiologic Solutions, EpiPointe, Epivax, EpiVax Therapeutics, Epygen Biotech, Equilab International, Er-Kim, Erasmus University Medical Center, Ergotron, Essity, ES Therapeutics, eTheRNA immunotherapies, Ethicon Endo-Surgery, Ethos Laboratories, Ethos Veterinary Health, Ethris, Eurobio, Eurocine Vaccines, EuroClone, Eurofarma, Eurofins Genomics, Eurofins Scientific, Eurofins Viracor, Euroimmun, European Biomedical Research Institute of Salerno, European Commission, European Investment Bank, European Prevention Center, European Union, EUSA Pharma, EvaClean, Evah, Evaxion Biotech, Everest Medicines, Everest Pharma, Evergreen Therapeutics, Everly Health, EverlyWell, Eversana, Evofem, Evogene, Evolve BioSystems, Evotec, EVQLV, Evrys Bio, Evvivax, Ewha Womans University, Exagen Diagnostics, ExcellGene, Excision BioTherapeutics, Excivion, Exeltis, ExeVir Bio, Exothera, Expedeon, Experimental Drug Development Centre, ExpreS2ion Biotechnologies, Express Scripts, ExScientia, ExThera Medical, Exyte, Eyam Vaccines and Immunotherapeutics, Eyegene, Eyevance, Fagron, FairJourney Biologics, Fannin, Fareva Holding, Farmacore Biotechnology, FarmaMondo Group, Fatro, Federal Ministry of Education and Research (BMBF), Fedora Pharmaceuticals, Feinstein Institute for Medical Research, Felix Biotechnology, Ferozsons Laboratories, Ferring Pharmaceuticals, FibroGenesis, Fidelta, Fina Biosolutions, Finch Therapeutics, Finnish Institute for Health and Welfare, Finorga, Fio, First Wave Bio, Fishbowl Warehouse, Fisher Healthcare, FitBit, Five Prime Therapeutics, Fleming Fund, Flightpath Biosciences, Flirtey, Florence, Florica Therapeutics, Florida International University, Florida State University, FlowMetric, Flow Pharma, Flowserve, FluGen, Fluidigm, Fluxergy, Folia Biotech, Food and Drug Administration (FDA), ForDoz Pharma, Forge Therapeutics, Forsitech, Fortive, Fosun Pharmaceutical, Foundation for Biomedical Research and Innovation, Foundation for Innovative New Diagnostics, Fox Chase Chemical Diversity Center, Fraunhofer Institute for Molecular Ecology (IME), Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Frazier Healthcare Ventures, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Fresenius Kabi Pharmaceuticals, Frontier Biotech, Frontier Scientific, Fujifilm, Fujifilm Diosynth Biotechnologies, FUJIFILM SonoSite, Fujirebio Diagnostics, Fujitsu Laboratories, Fulgent Genetics, Fundacion Medina, FYR Diagnostics, G-Tech Bio, G42 Healthcare, Gad Medical Equipment, Gaelan Medical, Galapagos, Galenvs Sciences, Gamaleya National Center, Gamidor Diagnostics, GAVI Alliance, GB Pharma Holdings, GBS, GC Pharma, Gedeon Richter, GE Healthcare, GEn1E Lifesciences, Genentech, GenePOC, General Motors, Generation Biotech, Generex Biotechnology, Genetic Immunity, Genetic Technologies, Genetron Health, GeNeuro, Geneva Foundation, Genevant Sciences, Genexine, Genexo, Genmab, Gennova Biopharmaceuticals, Genocea Biosciences, Genomadix, Genome Institute of Singapore, Genomma Lab Internacional, GenoScreen, GenScript Biotech, GenScript ProBio, GensKey Medical Technology, GenTegra, Geom Therapeutics, George Mason University, George Washington University, Georgia State University Research Foundation (GSURF), Georgia Tech Research Corporation, GeoVax, German Cancer Research Center, German Federal Ministry of Education and Research, German Government, Germinator, Getein Biotech, Getinge, Gibraltar Brothers and Associates, Gigagen, Gilead Sciences, Ginkgo BioWorks, Glaukos, GlaxoSmithKline, GlaxoSmithKline Biologicals, GL Capital Group, Glenmark Pharmaceuticals, Global Access Diagnostics, Global Antibiotic Research and Development Partnership, Global Coalition for Adaptive Research, Global Development Incubator, Global Dx, Global Good Fund, Global Health Innovative Technology Fund (GHIT), Global Response Aid, Global Virus Network, Global WholeHealth Partners, Globavir Biosciences, GlycoPath, GNA Biosolutions, Gnomegen, GNP Bioscience, Gnubiotics Sciences, Goffin Molecular Technologies, Golden Mountain Partners, Google, Government of Argentina, Government of Australia, Government of Bahrain, Government of Canada, Government of France, Government of Germany, Government of India, Government of Israel, Government of Japan, Government of Netherlands, Government of Serbia, Government of Singapore, Government of South Korea, Government of Switzerland, Government of The Philippines, GPCR Therapeutics, Grand River Aseptic Manufacturing, Gravity Diagnostics, Great Lakes Medical Laboratory, GreenBioAZ, Green Cross LabCell, Green Cross Medical Science, Greenfield Global, Greenlight Biosciences, Greenwich LifeSciences, Griffith University, Grifols, Gritstone Bio, Group K Diagnostics, GS, GSK Consumer Healthcare, GT Biopharma, GTCR Golder Rauner, GT Molecular, GTP Bioways, Guangzhou Institute of Respiratory Disease, Hackensack Meridian Health, Hai Kang Life, Hainan Sihuan Pharmaceutical, Hainan Visum Pharmaceutical, Haisco Pharmaceutical, Halberd, Halix, Halodine, Halomine, HaloVax, Halozyme Therapeutics, Hamilton Company, HanaVax, Hancom Group, Hannover Medical School, Harbour Biomed, Harro Hofliger, Harvard Medical School, Harvard T.H. Chan School of Public Health, Harvard University, Hawaii Biotech, HDT Bio, Healgen Scientific, Healion Bio, HEALTH Biomed, Healthcare Royalty Partners, Healthe, Health Holland, HealthTab, HealthTrackRx, Healthvana, Health Vector, Heat Biologics, HEC Pharm, Helix, Helix2, HelixBind, Helix BioPharma, Helmholtz Centre for Infection Research, Helocyte, Helperby Therapeutics, Hememics Biotechnologies, Hemex Health, Hennepin Life Sciences, Henry M. Jackson Foundation, Henry Schein, Hepatitis B Foundation, Hetero India, Hetero Labs, Heumann Pharma Generics, HHS Technology Group, HiFiBio, Hikma Pharmaceuticals, HilleVax, HiMedia Laboratories, Histogen, HistoGeneX, Hisun BioRay, HitGen, HIV Interactions in Viral Evolution (HIVE) Center, HLS Therapeutics, Hoffmann La Roche, Hologic, Hong Kong Polytechnic University, Honor Epic Enterprises, Hookipa Pharma, Hoowaki, Horizon Discovery, Horizon Europe, Hoth Therapeutics, Hovione, Howard Hughes Medical Institute (HHMI), HP, Hsiri Therapeutics, HSRx Group, HSS, HTC ChemRar, Hualan Biological Bacterin, Humabs BioMed, Humanigen, Hvidovre Hospital, hVIVO, Hybridize Therapeutics, Hygea Precision Medicine, Hygio, Hyloris Pharmaceuticals, I-MED Pharma, Iaso Therapeutics, iBio, IBM, Icahn School of Medicine at Mount Sinai, ICB Pharma, Ichor Biologics, Ichor Blood Services, Ichor Medical Systems, Icon, Iconovo, IDBiologics, IDbyDNA, IdentifySensors Biologics, ID Genomics, IDT Biologika, IES Diagnostics, iFLYTEK, IGM Biosciences, ILiAD Biotechnologies, Illumina, ILUM Health Solutions, ImageMover, Imagene Labs, Imbed Bio, Imec, ImmBio, Immorna, Immune Biosolutions, ImmuneCyte Life Sciences, Immune Regulation, Immune System Regulation, Immune Therapeutics, Immunetics, Immunexpress, ImmunityBio, Immuno Diagnostic, Immunome, Immunomic Therapeutics, ImmunoPrecise Antibodies, ImmunoQure, ImmunoScape, ImmunoTek Bio Centers, Immunovaccine, Immunyx Pharma, Immuron, Impax Laboratories, Imperial College London, ImQuest BioSciences, ImQuest Life Sciences, Imugen, Imutex, InBios International, IncellDx, InDevR, Indiana University, Indian Council of Medical Research, Indian Institute of Science Education and Research, IndyGeneUS AI, Infection Innovation Consortium, Infectious Disease Research Institute (IDRI), Infectolab Americas, InfectoPharm, Infex Therapeutics, Infinity BiologiX, Inflammatix, InflaRx, Infor, InfoRLife, Infrared Cameras, InfYnity Biomarkers, Ingenza, Inhalon Biopharma, Inhibitor Therapeutics, Inhibrx, InnoCentive, InnoPharmax, Innosuisse, InnoTech Precision Medicine, Innovare, Innovasource, Innovate Biopharmaceuticals, Innovate UK, Innovation Pharmaceuticals, Innovation Skane, Innoviva, Innovo, Inotrem, iNova Pharmaceuticals, Inovio, Inovio Pharmaceuticals, Inphilco, Inpixon, Inserm, Inserm Transfert, Insilico Medicine, Insmed Inc, Inspira Pharmaceuticals, Inspira Technologies, Inspyr Therapeutics, Instem, Institute for Bioscience and Biotechnology Research, Institute for Systems Biology, Institute for Transformative Technologies, Institute of Human Virology, Institute of Materia Medica, Institute of Virology and Immunology, Instituto Mato-grossense do Algodão, Institut Pasteur, Institut Pasteur of Shanghai at the Chinese Academy of Sciences, INTACT Solutions, Intarcia Therapeutics, Integral Molecular, Integrated BioTherapeutics, Integrated Computer Solutions, Integrated DNA Technologies, Integumen, Intel, Intelligence Advanced Research Projects Activity (IARPA), Intent Solutions, Interlab INTERAUTOMATIKA UAB, Intermodeco 2004, Intermountain Healthcare, International AIDS Vaccine Initiative, International Association of Providers of AIDS Care, International Center for Genetic Engineering and Biotechnology, International Centre for Diarrhoeal Disease Research, International Consortium on Anti-Virals, International Flavors and Fragrances, International Isotopes, International Vaccine Institute (IVI), Intralytix, Intravacc, iNtRON Biotechnology, IntuitiveX, InveniAI, Inventprise, Invivyd, InVixa, InvoSurg, INVZBL, IONTAS, IP Biotech, ipCapital Group, Ipsen, iQ Group, IQVIA, IRBM, iRemedy Healthcare Companies, IriSys, Isagro, ISA Pharmaceuticals, IsoPlexis, IsoTherapeutics, iSpecimen, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Israel Investment Center, Italfarmaco, Italian Government, Iterum Therapeutics, ITOCO, Iwatani Group, Jabil, James M Cox Foundation, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Therapeutics, Japan Agency for Medical Research and Development, Japan Government, Japan Tobacco, Jayne Koskinas Ted Giovanis Foundation for Health and Policy, Jenner Institute, Jhpiego, Jiangsu Carephar Pharmaceutical, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Egens Biotechnology, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jinvator Bio Med, JN Nova Pharma, John Hopkins University School of Medicines, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Medicine (JHM), Johns Hopkins University, John Snow, Johnson & Johnson, Johnson & Johnson Innovation, Jomo Kenyatta University of Agriculture and Technology, JSC Pharmadis, JSR, Jubilant Hollisterstier, Jubilant Life Sciences, Jubilant Pharma, Jubilant Therapeutics, Jumpcode Genomics, Jump Start Manufacturing, Junshi Biosciences, Just Biotherapeutics, Kadmon Pharmaceuticals, KaHa, Kaivogen, Kaken Pharmaceutical, Kalos Therapeutics, Kamada, Kane Biotech, Kaneka, Kansas City Area Life Sciences Institute, Kansas State University, Kantaro Biosciences, KARE Biosciences, Karius, Karolinska Institute, Karo Pharma, Karyopharm Therapeutics, Kasten, Katalyst Diagnostics, KBI BioPharma, KBio, Kedrion Biopharma, Kemin Industries, kENUP Foundation, Kenya Medical Research Institute, Kermode Biotechnologies, Keyence, KeyTronic, Kiadis Pharma, Kindred Bio, Kineta, King Abdullah University for Science and Technology, King Saud University, Kings College London, Kinnear Pharmaceuticals, Kintor, Kiromic Biopharma, Kishida Chemical, Kleen Bee Labs, Kleo Pharmaceuticals, KMG International, Knight Therapeutics, KNOW Bio, Komodo Health, Korea Advanced Institute of Science and Technology, Korrus, KorvaLabs, KPM Tech, Kukbo, Kurabo, Kurve Technology, Kuwait Government, KVK-Tech, Kyowa Hakko Kirin, L1 Systems, L7 Informatics, Laboratoire M2, Laboratorios Farmaceuticos Rovi, Laboratory Corporation of America, Labquality, Labrox, Lactiga, La Jolla Institute for Allergy & Immunology, La Jolla Pharmaceutical, LakePharma, LamdaGen, Lannett, Last Chance for Children, Latham BioPharm Group, Laurus Labs, Lawrence Livermore National Laboratory, Laxai Pharma, Laxisam, Leader Life Sciences, Leading BioSciences, LegoChem Biosciences, Leibniz-Institut fur Molekulare Pharmakologie, Leiden University, Leidos, Leinco Technologies, Lenovo, LEO Pharma, Les Laboratoires Servier, Leukocare, Levitee Labs, LexaGene, Leyden Laboratories, LFB Biotechnologies, LFB Group, LGC, LianBio, Libbs Farmaceutica, LifeArc, Lifebit Biotech, LifeLabs Medical Laboratory Services, Ligand Pharmaceuticals, Light Chain Bioscience, LightDeck Therapeutics, Li Ka Shing Foundation, Liminal BioSciences, Linical, LinKinVax, Lion TCR, Lipigon Pharmaceuticals, List Biological Laboratories, LiteVax, LiveLeaf, Liverpool School of Tropical Medicine, LiveRx Research Group, Livzon Mabpharm, Locus Biosciences, LogicBio Therapeutics, LogicInk, Longeveron, Longhorn Vaccines and Diagnostics, Longitude Capital, Lonza, Loop Insights, Loreal, Los Angeles County Department of Health Services, Louisiana State University, LSU Health Sciences Center, Lucence, Lucira Health, Lumen Biomedical, Luminare, Luminarie, Luminex, Luminostics, LuminUltra, LumiraDx, Lumos Diagnostics, Lumos Pharma, Lung Biotechnology, Lupin, Lupin Pharmaceuticals, Luxna Biotech, Lyndra Therapeutics, Lysando, Lytica Therapeutics, MaaT Pharma, mAbXience, Macau University of Science and Technology, Macleods Pharmaceuticals, Macquarie University, Macrolide Pharma, Macromoltek, Macrostruct Holding & Consulting, Maersk-Andersen, Magenta Investments, Magentine, Magle Chemoswed, MagnaCare, Mainz University Medical Centre, Maitri Health Technologies, MAJL Diagnostics, Mallinckrodt Pharmaceuticals, Mammoth Biosciences, Manhattan BioSolutions, Mannin Research, MannKind Biopharmaceuticals, Manny Pacquiao Foundation, Mapp Biopharmaceutical, March of Dimes, Marinomed Biotechnologie, Marken, Markforged, Marrone Bio Innovations, Maryland Technology Development Corporation, Masimo, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, MassBiologics, Mass General Brigham, Mast Group, Mast Therapeutics, Mateon Therapeutics, Mathematica, Matinas Biopharma, Matrivax, Matrix Biomed, Matrix Medical Network, Maverick Health, MAVIDx, Max-Planck, Max Biopharma, Maxcyte, Maxim Biomedical, Maxor National Pharmacy, Mayo Clinic, Mayo Clinical Ventures, MBio Diagnostics, McGill University, McKesson, McMaster University, MD Biosciences, Meadowlands Diagnostics, MEDCIS Pathlabs, Medela, Medicago, Medical Research Futures Fund, Medical Technology Enterprise Consortium, Medical University of Vienna, Medicinal Genomics, Medicines360, Medicines Development for Global Health, Medicines Patent Pool Foundation, MediciNova, Medicom, Medigen Biotechnology, MediGene, Medigen Vaccine Biologics, Medigus, MediMergent, MedImmune, MedinCell, Mediphos, Medison Pharma, Medisur, Meditemi, Medivant Healthcare, Medivir, Medizone International, Medlab Clinical, Medline Industries, MedMira, Medolife Rx, Medusa19, Medytox, Meihua International Medical Technologies, Meiji Seika, Meitheal Pharmaceuticals, Mekics, Melinta Therapeutics, Melior Pharmaceuticals, MeMed, Memorial Sloan Kettering Cancer Center, Memo Therapeutics, Menarini, Menarini Silicon Biosystems, Menon Biosensors, Mentholatum Company, Merck and Co, Merck Animal Health, Merck KGaA, Merck Sharpe & Dohme, Meridian Bioscience, Meridian Health Services Network, Meridian IT, Meridian Medical Technologies, MerLion, Mesa Biotech, Mesa Laboratories, Mesoblast, Metaclipse Therapeutics, MetrioPharm, Mexican National Technology and Science Council, Mexico Government, MGI Pharma, MGI Tech, Michigan State University, Micreos, MicrobeDx, Microbion, Microbiotix, Microbix Biosystems, MicroCoat Biotechnologie, MicroGEM, Micron Biomedical, Microprofit Biotech, MicroQuin, Microsoft, MicuRx Pharmaceuticals, Mid-Atlantic BioTherapeutics, Midatech, Midge Medical, miDiagnostics, Mie University, MigVax, MILA International, Milenia Labs, MilliporeSigma, MiMedx, Mimetas, Minapharm, MinervaX, Ministry of Health, Ministry of Health (Brazil), Ministry of Health (Denmark)


For a full list please contact us on


Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.